Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 3, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has reached...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials